Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPRAZOLAM vs BIAXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
Acute bacterial exacerbation of chronic bronchitis,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Helicobacter pylori eradication (as part of triple or dual therapy),Mycobacterium avium complex prophylaxis and treatment (off-label for some indications)
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Primarily metabolized by CYP3A4 isoenzyme; clarithromycin undergoes first-pass metabolism to form 14-hydroxyclarithromycin (active metabolite).
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
80% (primarily to albumin, minor to α1-acid glycoprotein)
65-75% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
Vd: 2.6-3.5 L/kg. Clinical meaning: Large Vd indicates extensive tissue penetration, including lungs, tonsils, and sinuses, exceeding serum concentrations.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
Oral bioavailability: 50-55% (250 mg tablet); may be increased to 60-70% when administered with food. Intravenous: 100%.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
Cr Cl <30 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: not recommended; no adjustment for Cr Cl >30 m L/min
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class C: reduce dose by 50% or consider alternative; mild to moderate hepatic impairment: no adjustment
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
15 mg/kg/day orally divided every 12 hours; maximum 500 mg/day for 10 days; for extended-release, not recommended for children <12 years
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
No specific dose adjustment; monitor renal function and adjust per renal guidelines; increased risk of QT prolongation
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
None
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Increased risk of cardiac arrhythmias, including QT prolongation and torsades de pointes; avoid in patients with known QT prolongation or concurrent use with QT-prolonging drugs.,Potential for hepatotoxicity (elevated liver enzymes, hepatitis); monitor liver function.,Exacerbation of myasthenia gravis symptoms.,Clostridioides difficile-associated diarrhea (CDAD).,Drug interactions via CYP3A4 inhibition (e.g., statins, warfarin, colchicine, and other macrolides).,Pregnancy Category C; avoid use unless no alternative (clarithromycin associated with increased risk of miscarriage and fetal abnormalities in animal studies).
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.,Concurrent use with pimozide, ergotamine, dihydroergotamine, lovastatin, simvastatin, or colchicine in renal/hepatic impairment.,History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.,QT prolongation or history of ventricular arrhythmias (including torsades de pointes).,Concurrent use with antiarrhythmics (e.g., quinidine, procainamide, amiodarone) or other QT-prolonging drugs.,Severe hepatic failure or acute porphyria.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and may increase clarithromycin levels, raising risk of QT prolongation. High-fat meals may delay absorption but do not significantly alter total exposure. Alcohol is not specifically contraindicated but may increase gastrointestinal irritation; avoid concurrent use of statins (especially simvastatin, lovastatin) due to increased myopathy risk.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First trimester: Avoid unless benefit justifies risk. Second and third trimesters: Limited data; use only if clearly needed. Monitor for potential maternal hepatotoxicity.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
Clarithromycin is excreted into human breast milk; the milk-to-plasma ratio is approximately 0.25-0.5. Infants exposed via breast milk may experience gastrointestinal disturbances or altered gut flora. Use with caution, especially in infants younger than 6 weeks of age due to risk of hypertrophic pyloric stenosis. Consider temporary discontinuation during therapy if high doses are used.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
No specific pharmacokinetic studies have demonstrated a need for dose adjustment during pregnancy. However, pregnancy can increase volume of distribution and renal clearance; empirical dose monitoring is not required. Standard dosing regimens are applied unless hepatic or renal impairment is present.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
Biaxin (clarithromycin) is a macrolide antibiotic with activity against atypical pathogens (e.g., Legionella, Mycoplasma, Chlamydia). It is a potent CYP3A4 inhibitor, increasing levels of statins, warfarin, and colchicine. Use caution in myasthenia gravis; may exacerbate weakness. QT prolongation risk: avoid use with other QT-prolonging drugs, correct electrolyte abnormalities. For H. pylori eradication, combine with amoxicillin and a PPI as first-line. Renal dose adjustment required for Cr Cl <30 m L/min.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
Take with or without food, but taking with food may reduce stomach upset.,Complete the full course even if you feel better to prevent resistance.,Avoid grapefruit or grapefruit juice while on this medication.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea/vomiting.,May cause metallic or bitter taste in the mouth; this is usually temporary.,Tell your doctor if you have myasthenia gravis, as clarithromycin can worsen symptoms.,Avoid driving or operating heavy machinery if you experience dizziness or vision changes.,Use effective contraception if applicable; clarithromycin may reduce oral contraceptive efficacy.
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPRAZOLAM vs BIAXIN, answered by our medical review team.
ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. BIAXIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPRAZOLAM and BIAXIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. The standard adult dose of BIAXIN is: 250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPRAZOLAM and BIAXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. BIAXIN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.